Histological remission of eosinophilic esophagitis under asthma therapy with IL-5 receptor monoclonal antibody: A case report

BACKGROUND: Benralizumab is a monoclonal antibody targeting the IL-5 receptor used in the treatment of asthma. The use of benralizumab in other conditions is only emerging and could represent a therapeutic option for other eosinophil-associated diseases. Here, we report the case of a patient suffering from eosinophilic esophagitis and asthma who achieved histological remission of eosinophilic esophagitis (EoE) under benralizumab treatment for his asthma. CASE SUMMARY: Our patient was a 56-year-old white male with a history of eosinophilic esophagitis and severe asthma. After years of usual treatments, including topical steroids, biological treatment with mepolizumab, and standard asthma treatment, only poor control of both conditions was obtained. A control gastroscopy after the initiation of benralizumab showed complete histological remission of his EoE. CONCLUSION: Our case shows the effects of therapy with a novel agent not yet approved for this condition but for other diseases, with histological resolution of EoE after treatment. Complete clinical remission was not observed, which exemplifies the complex nature of EoE, its associated psychosomatic burden, and the chronification of the disease. Nevertheless, monoclonal antibodies targeting the Th2 response and, in our case, an IL5 receptor antagonist, achieved complete histological remission, which was not the case with an antibody against IL-5, which was also initiated to treat asthma.